These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36323537)

  • 1. [Chinese expert consensus on clinical practice of MET detection in non-small cell lung cancer].
    ; ; ; ;
    Zhonghua Bing Li Xue Za Zhi; 2022 Nov; 51(11):1094-1103. PubMed ID: 36323537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chinese expert consensus on MET immunohistochemistry detection and interpretation standards for non-small cell lung cancer(2023 version)].
    ;
    Zhonghua Bing Li Xue Za Zhi; 2023 Nov; 52(11):1090-1097. PubMed ID: 37899313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expert consensus on clinical practice of fusion genes detection in non-small cell lung cancer in China (2023 version)].
    ; ;
    Zhonghua Bing Li Xue Za Zhi; 2023 Jun; 52(6):565-573. PubMed ID: 37263920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chinese Expert Consensus on Next Generation Sequencing Diagnosis 
for Non-small Cell Lung Cancer (2020 Edition)].
    Chinese Society of Clinical Oncology, Expert Committee on Non-small Cell Lung Cancer
    Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):741-761. PubMed ID: 32957170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expert consensus on clinical practice of RET fusion detection in non-small cell lung cancer in China].
    ; ;
    Zhonghua Bing Li Xue Za Zhi; 2021 Jun; 50(6):583-591. PubMed ID: 34078044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chinese expert consensus on the multidisciplinary clinical diagnosis and treatment of stage Ⅲ non-small cell lung cancer (2019)].
    ;
    Zhonghua Zhong Liu Za Zhi; 2019 Dec; 41(12):881-890. PubMed ID: 31874543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expert consensus on clinical practice of molecular tests in non-small cell lung cancer with malignant effusion in China].
    Cytology Section, Chinese Society of Pathology
    Zhonghua Bing Li Xue Za Zhi; 2022 Dec; 51(12):1198-1204. PubMed ID: 36480826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Screen of ALK-positive non-small cell lung cancer by routine immunohistochemistry: an expert consensus].
    Consensus Group for screen of ALK-positive non-small cell lung cancer by routine immunohistochemistry
    Zhonghua Bing Li Xue Za Zhi; 2015 Jul; 44(7):476-9. PubMed ID: 26705037
    [No Abstract]   [Full Text] [Related]  

  • 9. [Consensus on dignosis for ALK positive non-small cell lung cancer in China, the 2013 version].
    Zhang XC; Lu S; Zhang L; Wang CL; Cheng Y; Li GD; Mok T; Huang C; Liu XQ; Wang J; Wang MZ; Zhang YP; Zhou JY; Zhou XY; Lin DM; Yang JJ; Li H; Chen HQ; Zhong WZ; Wu YL
    Zhonghua Bing Li Xue Za Zhi; 2013 Jun; 42(6):402-6. PubMed ID: 24060077
    [No Abstract]   [Full Text] [Related]  

  • 10. [Expert consensus on PD-L1 expression testing in non-small-cell lung cancer in China].
    ; ;
    Zhonghua Zhong Liu Za Zhi; 2020 Jul; 42(7):513-521. PubMed ID: 32842436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expert consensus on the pathological diagnosis of small biopsy specimens of lung cancer].
    ;
    Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):333-340. PubMed ID: 36973192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The Guideline for Diagnosis and Treatment of Chinese Patients with sensitizing EGFR Mutation or ALK Fusion Gene-Positive Non-Small Cell Lung Cancer (2015 Version)].
    ;
    Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):796-9. PubMed ID: 26813604
    [No Abstract]   [Full Text] [Related]  

  • 13. Response to letter entitled: letter comments on: Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation.
    Gosney JR; Peters S
    ESMO Open; 2023 Oct; 8(5):101828. PubMed ID: 37820563
    [No Abstract]   [Full Text] [Related]  

  • 14. [Expert consensus on clinical practice of ALK fusion detection in non-small cell lung cancer in China].
    ;
    Zhonghua Bing Li Xue Za Zhi; 2019 Dec; 48(12):913-920. PubMed ID: 31818063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chinese expert consensus on Anlotinib Hydrochloride for advanced lung cancer (2020 edition)].
    ; ;
    Zhonghua Zhong Liu Za Zhi; 2020 Oct; 42(10):807-816. PubMed ID: 33113621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chinese expert consensus on stereotactic body radiation therapy for early stage non-small cell lung cancer (2019 Edition)].
    ; ;
    Zhonghua Zhong Liu Za Zhi; 2020 Jul; 42(7):522-530. PubMed ID: 32842437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Lung cancer: progress in diagnosis and treatments. Topics: IV. Recent topics; 1. Driver mutations in non-small cell lung cancer].
    Mano H
    Nihon Naika Gakkai Zasshi; 2014 Jun; 103(6):1355-9. PubMed ID: 25151801
    [No Abstract]   [Full Text] [Related]  

  • 18. [Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2022 edition)].
    ;
    Zhonghua Zhong Liu Za Zhi; 2022 Oct; 44(10):1047-1065. PubMed ID: 36319450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of microRNA-25 in patients with non-small cell lung cancer in Chinese population: A systematic review and meta-analysis.
    Li C; Sun L; Zhou H; Yang Y; Wang Y; She M; Chen J
    Medicine (Baltimore); 2020 Dec; 99(51):e23425. PubMed ID: 33371070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chinese Expert Consensus on Standards of PD-L1 Immunohistochemistry Testing 
for Non-small Cell Lung Cancer].
    ; ;
    Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):733-740. PubMed ID: 32957169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.